Albert A. Antolin
Albert A. Antolin
ICR Fellow / Junior Team Leader, The Institute of Cancer Research, UK
Verified email at - Homepage
Cited by
Cited by
In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities
C Rubio-Perez, D Tamborero, MP Schroeder, AA Antolín, J Deu-Pons, ...
Cancer cell 27 (3), 382-396, 2015
Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen
MP Menden, D Wang, MJ Mason, B Szalai, KC Bulusu, Y Guan, T Yu, ...
Nature communications 10 (1), 2674, 2019
canSAR: an updated cancer research and drug discovery knowledgebase
JE Tym, C Mitsopoulos, EA Coker, P Razaz, AC Schierz, AA Antolin, ...
Nucleic acids research 44 (D1), D938-D943, 2016
The kinase polypharmacology landscape of clinical PARP inhibitors
AA Antolin, M Ameratunga, U Banerji, PA Clarke, P Workman, ...
Scientific reports 10 (1), 2585, 2020
Polypharmacology in precision oncology: current applications and future prospects
A A Antolin, P Workman, J Mestres, B Al-Lazikani
Current pharmaceutical design 22 (46), 6935-6945, 2016
canSAR: update to the cancer translational research and drug discovery knowledgebase
C Mitsopoulos, P Di Micco, EV Fernandez, D Dolciami, E Holt, IL Mica, ...
Nucleic acids research 49 (D1), D1074-D1082, 2021
Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology
AA Antolin, X Jalencas, J Yelamos, J Mestres
ACS chemical biology 7 (12), 1962-1967, 2012
Objective, quantitative, data-driven assessment of chemical probes
AA Antolin, JE Tym, A Komianou, I Collins, P Workman, B Al-Lazikani
Cell chemical biology 25 (2), 194-205. e5, 2018
Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors
AA Antolín, J Mestres
Oncotarget 5 (10), 3023, 2014
canSAR: update to the cancer translational research and drug discovery knowledgebase
EA Coker, C Mitsopoulos, JE Tym, A Komianou, C Kannas, P Di Micco, ...
Nucleic acids research 47 (D1), D917-D922, 2019
Identification of different side effects between PARP inhibitors and their polypharmacological multi‐target rationale
D Sandhu, AA Antolin, AR Cox, AM Jones
British Journal of Clinical Pharmacology 88 (2), 742-752, 2022
Target 2035–update on the quest for a probe for every protein
S Müller, S Ackloo, A Al Chawaf, B Al-Lazikani, A Antolin, JB Baell, ...
RSC Medicinal Chemistry 13 (1), 13-21, 2022
Transforming cancer drug discovery with Big Data and AI
P Workman, AA Antolin, B Al-Lazikani
Expert opinion on drug discovery 14 (11), 1089-1095, 2019
Distant polypharmacology among MLP chemical probes
AA Antolin, J Mestres
ACS Chemical Biology 10 (2), 395-400, 2015
Public resources for chemical probes: the journey so far and the road ahead
AA Antolin, P Workman, B Al-Lazikani
Future Medicinal Chemistry 13 (08), 731-747, 2021
The Chemical Probes Portal: an expert review-based public resource to empower chemical probe assessment, selection and use
AA Antolin, D Sanfelice, A Crisp, E Villasclaras Fernandez, IL Mica, ...
Nucleic acids research 51 (D1), D1492-D1502, 2023
Exploring the effect of PARP-1 flexibility in docking studies
AA Antolin, A Carotti, R Nuti, A Hakkaya, E Camaioni, J Mestres, ...
Journal of Molecular Graphics and Modelling 45, 192-201, 2013
Evolution of kinase polypharmacology across HSP90 drug discovery
AA Antolin, PA Clarke, I Collins, P Workman, B Al-Lazikani
Cell Chemical Biology 28 (10), 1433-1445. e3, 2021
canSAR chemistry registration and standardization pipeline
D Dolciami, E Villasclaras-Fernandez, C Kannas, M Meniconi, ...
Journal of Cheminformatics 14 (1), 28, 2022
Rare variation in drug metabolism and long QT genes and the genetic susceptibility to acquired long QT syndrome
B Gray, AE Baruteau, AA Antolin, A Pittman, G Sarganas, M Molokhia, ...
Circulation: Genomic and Precision Medicine 15 (1), e003391, 2022
The system can't perform the operation now. Try again later.
Articles 1–20